Niraparib for advanced tumors with DNA repair defects
Treatments studied
Part of Cancer clinical trials.
This trial tests a pill called niraparib (brand name ZEJULA) in people with advanced solid tumors that have DNA repair problems (called HRD). The drug targets cancer cells with these repair defects, potentially slowing or stopping tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have a solid tumor that is advanced (has spread or cannot be removed by surgery).
- You have a known harmful change in DNA repair genes (like BRCA) or a test showing your tumor has DNA repair problems.
- You are willing to provide a tumor sample (biopsy) for central testing.
- You have never taken a PARP inhibitor (like olaparib or rucaparib).
- Your cancer did not resist platinum chemotherapy (like cisplatin or carboplatin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
This trial studies talazoparib (a targeted pill) in people with advanced breast cancer whose tumors have problems repairing certain DNA damage. If your tumor has these specific “DNA repair” defects, the medicine may work better and stop the cancer from growing.
This trial studies a new drug called saruparib for people with certain solid tumors that have a specific DNA repair problem (called HRD). It may help if your cancer has progressed after other treatments.
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
This trial tests a new drug called AZD4956, alone or with other cancer medicines, for people with advanced solid tumors that have certain DNA repair problems (called homologous recombination deficiency). It may be an option if you have breast, ovarian, prostate, or pancreatic cancer with a specific gene change, and you have or haven't had previous PARP inhibitor treatment.
This trial tests a drug that may help people with advanced breast cancer who have a specific genetic change (in the PALB2 gene). The drug is a PARP inhibitor, which works by targeting cancer cells that have trouble repairing their DNA.
Hear when a new Efficacy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.